HK$14.01
10.32%
Hong Kong, Sep 18, 03:50 pm HKT. Closed.
Why the stock moved Why the stock moved Beta
ISIN
KYG4403H1002
Symbol
2142

Hbm Holdings Stock price

HK$14.05
-0.97 6.46% 1M
+1.60 12.85% 6M
+1.89 15.54% YTD
-1.41 9.12% 1Y
+12.44 772.67% 3Y
+7.11 102.45% 5Y
+3.03 27.50% 10Y
+3.03 27.50% 20Y
Hong Kong, Closing price Fri, Sep 18 2026
+1.35 10.63%
ISIN
KYG4403H1002
Symbol
2142
Industry

Is Hbm Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$11.1b
Enterprise Value
HK$8.6b
Net debt
positive
Cash
HK$3.2b
Shares outstanding
868.7m
Valuation (TTM | estimate)
P/E
14.0
P/S
8.9 | 5.9
EV/Sales
6.9 | 4.6
EV/FCF
15.7
P/B
3.8
Financial Health
Equity Ratio
73.4%
Return on Equity
24.9%
ROCE
22.2%
ROIC
131.3%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
HK$1.2b | HK$1.9b
EBITDA
HK$741.8m
EBIT
HK$722.0m
Net Income
HK$716.6m
Free Cash Flow
HK$545.9m
Growth (TTM | estimate)
Revenue
314.6% | 50.5%
EBITDA
998.3%
EBIT
1,507.9%
Net Income
3,187.1%
Free Cash Flow
128.6%
Margin
Gross
94.5%
EBITDA
59.9%
EBIT
58.3%
Net
57.8%
Free Cash Flow
44.1%
More
EPS
HK$0.9
FCF per Share
HK$0.6
Short interest
-
Employees
272
Rev per Employee
HK$4.6m

Hbm Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Hbm Holdings forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Hbm Holdings forecast:

Buy
89%
Hold
11%

Financial data from Hbm Holdings

Dec '25
+/-
%
1,239 1,239
315% 315%
100%
- Direct Costs 69 69
95% 95%
6%
1,171 1,171
344% 344%
94%
- Selling and Administrative Expenses 227 227
82% 82%
18%
- Research and Development Expense 312 312
89% 89%
25%
742 742
998% 998%
60%
- Depreciation and Amortization 20 20
12% 12%
2%
EBIT (Operating Income) EBIT 722 722
1,508% 1,508%
58%
Net Profit 717 717
3,187% 3,187%
58%

In millions HKD.

Don't miss a Thing! We will send you all news about Hbm Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

HBM Holdings Ltd. is an investment company, which engages in the discovery and development of differentiated antibody therapeutics in oncology and immunology disease areas. The company is headquartered in Suzhou, Jiangsu and currently employs 237 full-time employees. The company went IPO on 2020-12-10. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The firm provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.

Head office Cayman Islands
CEO Dr. Jingsong
Employees 272
Website www.harbourbiomed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today